aTYR PHARMA INC — Director's Dealing 2019

May 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2019-05-16

Reporting Person: Krueger Nancy (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-16	Common Stock	M	12500	$0.00	Acquired	29999	Direct
2019-05-17	Common Stock	S	4651	$0.4501	Disposed	25348	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-16	Restricted Stock Units	$0.00	M	12500	Disposed		Common Stock (12500)	Direct

Footnotes

F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on May 16, 2018.

F2: Includes 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2019.

F3: Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on May 16, 2018.

F4: The RSU grant vests as to one-half (1/2) of the total number of units on each one year anniversary of the grant commencing on May 16, 2019.